Literature DB >> 29760082

A cytokine network involving IL-36γ, IL-23, and IL-22 promotes antimicrobial defense and recovery from intestinal barrier damage.

Vu L Ngo1, Hirohito Abo1, Estera Maxim1, Akihito Harusato1, Duke Geem1, Oscar Medina-Contreras1, Didier Merlin2,3, Andrew T Gewirtz1, Asma Nusrat4, Timothy L Denning5.   

Abstract

The gut epithelium acts to separate host immune cells from unrestricted interactions with the microbiota and other environmental stimuli. In response to epithelial damage or dysfunction, immune cells are activated to produce interleukin (IL)-22, which is involved in repair and protection of barrier surfaces. However, the specific pathways leading to IL-22 and associated antimicrobial peptide (AMP) production in response to intestinal tissue damage remain incompletely understood. Here, we define a critical IL-36/IL-23/IL-22 cytokine network that is instrumental for AMP production and host defense. Using a murine model of intestinal damage and repair, we show that IL-36γ is a potent inducer of IL-23 both in vitro and in vivo. IL-36γ-induced IL-23 required Notch2-dependent (CD11b+CD103+) dendritic cells (DCs), but not Batf3-dependent (CD11b-CD103+) DCs or CSF1R-dependent macrophages. The intracellular signaling cascade linking IL-36 receptor (IL-36R) to IL-23 production by DCs involved MyD88 and the NF-κB subunits c-Rel and p50. Consistent with in vitro observations, IL-36R- and IL-36γ-deficient mice exhibited dramatically reduced IL-23, IL-22, and AMP levels, and consequently failed to recover from acute intestinal damage. Interestingly, impaired recovery of mice deficient in IL-36R or IL-36γ could be rescued by treatment with exogenous IL-23. This recovery was accompanied by a restoration of IL-22 and AMP expression in the colon. Collectively, these data define a cytokine network involving IL-36γ, IL-23, and IL-22 that is activated in response to intestinal barrier damage and involved in providing critical host defense.

Entities:  

Keywords:  inflammatory bowel disease; innate immunity; interleukin; repair

Mesh:

Substances:

Year:  2018        PMID: 29760082      PMCID: PMC5984499          DOI: 10.1073/pnas.1718902115

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  64 in total

Review 1.  The interleukin-1 family: back to the future.

Authors:  Cecilia Garlanda; Charles A Dinarello; Alberto Mantovani
Journal:  Immunity       Date:  2013-12-12       Impact factor: 31.745

2.  Increased Expression of Interleukin-36, a Member of the Interleukin-1 Cytokine Family, in Inflammatory Bowel Disease.

Authors:  Atsushi Nishida; Kentaro Hidaka; Toshihiro Kanda; Hirotsugu Imaeda; Makoto Shioya; Osamu Inatomi; Shigeki Bamba; Katsuyuki Kitoh; Mitsushige Sugimoto; Akira Andoh
Journal:  Inflamm Bowel Dis       Date:  2016-02       Impact factor: 5.325

3.  Inflammation: IL-36 has proinflammatory effects in skin but not in joints.

Authors:  Damien Dietrich; Cem Gabay
Journal:  Nat Rev Rheumatol       Date:  2014-09-09       Impact factor: 20.543

4.  Functional specializations of intestinal dendritic cell and macrophage subsets that control Th17 and regulatory T cell responses are dependent on the T cell/APC ratio, source of mouse strain, and regional localization.

Authors:  Timothy L Denning; Brian A Norris; Oscar Medina-Contreras; Santhakumar Manicassamy; Duke Geem; Rajat Madan; Christopher L Karp; Bali Pulendran
Journal:  J Immunol       Date:  2011-06-10       Impact factor: 5.422

5.  IL-36R signalling activates intestinal epithelial cells and fibroblasts and promotes mucosal healing in vivo.

Authors:  Kristina Scheibe; Ingo Backert; Stefan Wirtz; Axel Hueber; Georg Schett; Michael Vieth; Hans Christian Probst; Tobias Bopp; Markus F Neurath; Clemens Neufert
Journal:  Gut       Date:  2016-01-18       Impact factor: 23.059

Review 6.  The emergence of the IL-36 cytokine family as novel targets for inflammatory diseases.

Authors:  Patrick T Walsh; Padraic G Fallon
Journal:  Ann N Y Acad Sci       Date:  2016-10-26       Impact factor: 5.691

Review 7.  Recent advances in IL-22 biology.

Authors:  Lauren A Zenewicz; Richard A Flavell
Journal:  Int Immunol       Date:  2011-03       Impact factor: 4.823

Review 8.  Interleukin-22-producing natural killer cells and lymphoid tissue inducer-like cells in mucosal immunity.

Authors:  Marco Colonna
Journal:  Immunity       Date:  2009-07-17       Impact factor: 31.745

9.  NLRP6 function in inflammatory monocytes reduces susceptibility to chemically induced intestinal injury.

Authors:  S S Seregin; N Golovchenko; B Schaf; J Chen; K A Eaton; G Y Chen
Journal:  Mucosal Immunol       Date:  2016-06-29       Impact factor: 7.313

10.  Notch2-dependent classical dendritic cells orchestrate intestinal immunity to attaching-and-effacing bacterial pathogens.

Authors:  Ansuman T Satpathy; Carlos G Briseño; Jacob S Lee; Dennis Ng; Nicholas A Manieri; Wumesh Kc; Xiaodi Wu; Stephanie R Thomas; Wan-Ling Lee; Mustafa Turkoz; Keely G McDonald; Matthew M Meredith; Christina Song; Cynthia J Guidos; Rodney D Newberry; Wenjun Ouyang; Theresa L Murphy; Thaddeus S Stappenbeck; Jennifer L Gommerman; Michel C Nussenzweig; Marco Colonna; Raphael Kopan; Kenneth M Murphy
Journal:  Nat Immunol       Date:  2013-08-04       Impact factor: 25.606

View more
  34 in total

1.  Candida albicans Elicits Pro-Inflammatory Differential Gene Expression in Intestinal Peyer's Patches.

Authors:  Navjot Singh; Heather C Kim; Renjie Song; Jaskiran K Dhinsa; Steven R Torres; Magdia De Jesus
Journal:  Mycopathologia       Date:  2019-06-22       Impact factor: 2.574

Review 2.  Intestinal epithelial cells: at the interface of the microbiota and mucosal immunity.

Authors:  Amelia T Soderholm; Virginia A Pedicord
Journal:  Immunology       Date:  2019-10-04       Impact factor: 7.397

3.  IL-36R signaling integrates innate and adaptive immune-mediated protection against enteropathogenic bacteria.

Authors:  Vu L Ngo; Hirohito Abo; Michal Kuczma; Edyta Szurek; Nora Moore; Oscar Medina-Contreras; Asma Nusrat; Didier Merlin; Andrew T Gewirtz; Leszek Ignatowicz; Timothy L Denning
Journal:  Proc Natl Acad Sci U S A       Date:  2020-10-21       Impact factor: 11.205

4.  Interleukin-22, a potent target for treatment of non-autoimmune diseases.

Authors:  Yue Zheng; Tong Li
Journal:  Hum Vaccin Immunother       Date:  2018-10-31       Impact factor: 3.452

5.  IL-33 promotes recovery from acute colitis by inducing miR-320 to stimulate epithelial restitution and repair.

Authors:  Loris R Lopetuso; Carlo De Salvo; Luca Pastorelli; Nitish Rana; Henry N Senkfor; Valentina Petito; Luca Di Martino; Franco Scaldaferri; Antonio Gasbarrini; Fabio Cominelli; Derek W Abbott; Wendy A Goodman; Theresa T Pizarro
Journal:  Proc Natl Acad Sci U S A       Date:  2018-09-17       Impact factor: 11.205

Review 6.  Interleukin-36: Structure, Signaling and Function.

Authors:  Li Zhou; Viktor Todorovic
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 7.  Immune Cell Circuits in Mucosal Wound Healing: Clinical Implications.

Authors:  Sebastian Zundler; Verena Tauschek; Markus F Neurath
Journal:  Visc Med       Date:  2020-03-13

Review 8.  IL-36 in chronic inflammation and fibrosis - bridging the gap?

Authors:  Michael Elias; Shuai Zhao; Hongnga T Le; Jie Wang; Markus F Neurath; Clemens Neufert; Claudio Fiocchi; Florian Rieder
Journal:  J Clin Invest       Date:  2021-01-19       Impact factor: 14.808

Review 9.  Interleukins in cancer: from biology to therapy.

Authors:  Daria Briukhovetska; Janina Dörr; Stefan Endres; Peter Libby; Charles A Dinarello; Sebastian Kobold
Journal:  Nat Rev Cancer       Date:  2021-06-03       Impact factor: 69.800

10.  Critical role of interferons in gastrointestinal injury repair.

Authors:  Constance McElrath; Vanessa Espinosa; Jian-Da Lin; Jianya Peng; Raghavendra Sridhar; Orchi Dutta; Hsiang-Chi Tseng; Sergey V Smirnov; Heidi Risman; Marvin J Sandoval; Viralkumar Davra; Yun-Juan Chang; Brian P Pollack; Raymond B Birge; Mark Galan; Amariliz Rivera; Joan E Durbin; Sergei V Kotenko
Journal:  Nat Commun       Date:  2021-05-11       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.